VERA Stock: Price, Earnings History and SEC Filings
Vera Therapeutics, Inc. (VERA) last traded at $30.98, up 1.47% on the latest session and down 4.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.52 against an analyst estimate of $-1.60, a beat of 5.0%.
$30.98 +1.47%
1 month-4.06%
52-week high$56.05
52-week low$23.05
Volume1.08M
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
VERA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 10, 2026 | $-1.52 | $-1.60 | +5.00% |
| Mar 2026 | May 7, 2026 | $-1.69 | $-1.26 | -34.13% |
| Dec 2025 | Feb 26, 2026 | $-1.39 | $-1.34 | -3.73% |
| Sep 2025 | Nov 5, 2025 | $-1.26 | $-1.20 | -5.00% |
VERA beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for VERA
SEC filing data is not available right now. You can search for VERA on SEC EDGAR.
VERA news
- Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy ResultsOct 23, 2026 · marketbeat.com
- Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of MedicineOct 22, 2026 · finance.yahoo.com
- Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference WebcastOct 20, 2026 · finance.yahoo.com
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc. (VERA) is a US-listed public company on Nasdaq.